Skip to contentF
Faeth Therapeutics, Inc.
F
FTHFaeth Therapeutics, Inc. Released Mar 10, 2022, before the open
10-K filed Mar 15, 2022, 74 days after period end · 0000950170-22-003646
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$9.37M-$9.37MderivedN/M vs Q4 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Faeth Therapeutics, Inc. · CIK 1829802 · Engraved from SEC EDGAR
N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$9,413,000N/M Operating Cash Flowderived-$7,868,000N/M Free Cash Flowderived-$8,403,000N/M ended Dec 31, 2021 · filed Mar 15, 2022 · 74 d after period end
12.3% from the close of Mar 8, 2022 to the close of Mar 11, 2022, the first after the release.
before the open$3.08$2.70 Feb 10Mar 10Apr 12